

Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,31, 1951
4,67, 1198132
3,25, 0
2,64, 0
2,53, 0
2,29, 0
2,03, 0

FIGURE 1 A



Absorbance (AU)
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,00, 0
2,27, 0
2,53, 0
4,67, 685885
5,28, 1337

FIGURE 1 B



Absorbance (AU)
0,16
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
Retention Time (min)
0
1
2
3
4
5
6
7
8
2,03, 0
2,29, 0
2,53, 0
2,64, 0
4,69, 832990
5,31, 1196

FIGURE 1 C



Absorbance (AU)
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,29, 0
2,51, 0
5,28, 82895
6,00, 1207

FIGURE 1 D



Absorbance (AU)
0,16
0,14
0,12
0,10
0,08
0,06
0,04
0,02
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,12, 1330
2,32, 0
2,53, 0
2,81, 0

FIGURE 1 E



Absorbance (AU)
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,07, 1326
2,03, 0
2,32, 0
2,53, 0

FIGURE 1 F



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,56, 0
2,37, C
2,06, 0

FIGURE 1 G



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
2,03, 0
2,32, 0
2,53, 0
4,32, 9974
4,85, 1167

FIGURE 2 A



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)
5,04, 1521
3,25, 0
2,53, 0
2,32, 0
2,03, 0

FIGURE 2 B

FIGURE 2 C



Absorbance (AU)
0,20
0,15
0,10
0,05
0,00
0
1
2
3
4
5
6
7
8
Retention Time (min)

Figure 3 A



Carbomer gel 2% (n=6)
HPMC E5 (7,95) / PEG 400 (1.98) (n=6)
HPMC E5 (7.95) / PEG 400 (3.97) (n=6)
HPMC E5 (7.95) without PEG (n=8)
HPMC E5 (6.36) / PEG 400 (3.97) (n=4)
HPMC E5 (3.97) / PEG 400 (1.98) (n=4)
HPMC E5 (3.97) / PEG 400 (3.97) (n=5)
HPMC E5 (15.91) / PEG 400 (1.98) (n=4)
HPMC E5 (15.91) / PEG 400 (3.97) (n=4)
% of cidofovir diffused
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Time (hours)

Figure 3 B



Carbomer gel 2% (n=6)
NaCMC (3.18) / PEG 400 (1.98) (n=2)
NaCMC (4.77) without PEG (n=4)
NaCMC (4.77) / PEG 400 (1.98) (n=4)
NaCMC (4.77) / PEG 400 (3.97) (n=4)
NaCMC (6.36) / PEG 400 (1.98) (n=2)
% of cidofovir diffused
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Time (hours)

Figure 3 C




HEC 250HX (7,95) / PEG 400 (1.98) (n=4)
Carbomer gel 2% (n=6)
HEC 250M (9.54) / PEG 400 (1.98) (n=4)
% of cidofovir diffused
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
Time (hours)

Figure 4


7100 19KU X25 1mm WD39



7082 19KU X25 1mm WD39
HPMC E5 (7,95 mg/cm²) / PEG 400 (1,98 mg/cm²) / cidofovir (4,77 mg/cm²)

Figure 5



7092 19KV X100 100µm WD39
HPMC E5 (7.95 mg/cm³) / PEG 400 (1.98 mg/cm³)
7113 19KV X100 100µm WD39
A
7084 19KV X100 100µm WD39
HPMC E5 (7.95 mg/cm³) / PEG 400 (1.98 mg/cm³) / cidofovir (4.77 mg/cm³)
7101 19KV X100 100µm WD39
B

Figure 6



A
B
7099 19KV X4,000 1μm WD38
HPMC E5 (7,95 mg/cm²) / PEG 400 (1,98 mg/cm²)
7089 19KV X4,000 1μm WD39
HPMC E5 (7,95 mg/cm²) / PEG 400 (1,98 mg/cm²) / cidofovir (4,77 mg/cm²)
7118 19KV X4,000 1μm WD38
7106 19KV X4,000 1μm WD39

Figure 7



A
B
7640 19KV X25 1mm WD39
HPMC E5 (7.95 mg/cm³) / PEG 400 (3.97 mg/cm³)
7645 19KV X25 1mm WD39
HPMC E5 (15.91 mg/cm³) / PEG 400 (3.97 mg/cm³)
7643 19KV X100 100µm WD39
HPMC E5 (7.95 mg/cm³) / PEG 400 (3.97 mg/cm³)
7648 19KV X100 100µm WD39
HPMC E5 (15.91 mg/cm³) / PEG 400 (3.97 mg/cm³)

Figure 8



A
B
7634 19KV X25 1mm WD39
HPMC E5 (7.95 mg/cm²) sans plastifiant
7638 19KV X100 100µm WD38
HPMC E5 (7.95 mg/cm²) sans plastifiant
7091 19KV X25 1mm WD39
HPMC E5 (7.95 mg/cm²) / PEG 400 (1.08 mg/cm²)
7096 19KV X100 100µm WD38
HPMC E5 (7.95 mg/cm²) / PEG 400 (1.08 mg/cm²)
7640 19KV X25 1mm WD39
HPMC E5 (7.95 mg/cm²) / PEG 400 (3.97 mg/cm²)
7643 19KV X100 100µm WD39
HPMC E5 (7.95 mg/cm²) / PEG 400 (3.97 mg/cm²)

Figure 9




A
B
7092 19KV X100 100µm WD39
HPMC E5 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³)
7620 19KV X100 100µm WD39
HPMC 4000 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³)
7630 19KV X100 100µm WD39
HPMC K15 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³)
7084 19KV X100 100µm WD39
HPMC E5 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³) / cidofovir (4,77 mg/cm³)
7654 19KV X100 100µm WD39
HPMC 4000 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³) / cidofovir (4,77 mg/cm³)
7625 19KV X100 100µm WD39
HPMC K15 (7,95 mg/cm³) / PEG 400 (1,98 mg/cm³) / cidofovir (4,77 mg/cm³)

Figure 10


19KV X25 1mm WD39
7721 19KV X25 1mm WD39
7736 19KV X100 100µm WD39
7722 19KV X100 100µm WD39



7738 19KV X4,000 1µm WD39
7723 19KV X750 10µm WD39
7724 19KV X4,000 1µm WD39

Figure 11




Figure 12 A

Figure 12 B



η (Pa.s)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
-0.2
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PEG (1.98) / CID
NaCMC (3.18) / PEG (1.98)
HPMC E15 (7.95) / PG (1.98)
HPMC E5 (11.93) / PEG (1.98)
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (7.95) / PEG (1.98) / CID
HPMC E5 (6.36) / PEG (1.98)
0
20.0
40.0
60.0
80.0
100.0
γ (1/s)

Figure 12 B



η (Pa.s)
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
NaCMC (4.77) / PEG (1.98)
NaCMC (4.77) / PG (1.98)
HPMC E5 (7.95) / PEG (1.98)
HPMC E5 (7.95) / PG (1.98)
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
γ (1/s)

Figure 13




Figure 14 A

Figure 14 B



η (Pa.s)
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0
09F05 (CID) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
gel HEC M 4% (η (Pa.s))
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
γ̇ (1/s)

Figure 14 B



η (Pa.s)
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0
09F05 (CID) (η (Pa.s))
HEC 250 HX (7.95) / PEG 400 (1.98) bis (η (Pa.s))
HEC 250 HX (7.95) / PEG 400 (1.98) bis (η (Pa.s))
gel HEC HX 3% bis (η (Pa.s))
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
γ̇ (1/s)

Figure 15




Figure 15 cont.

Figure16



η (Pa.s)
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0
-10.0
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
γ̇ (1/s)
HPMC K15 (7.95) / PEG 400 (1.98) (10G13-8) (η (Pa.s))
HPMC K4M (7.95) / HPC GF (3.97) / PEG 400 (3.97) 10H11-4 (η (Pa.s))
HPMC K4M (7.95) / HPC GF (3.97) / PEG 4000 (1.19) (10H11-6) (η (Pa.s))
HPMC K4M (7.95) / HPC GF (1.98) / PEG 400 (3.97) (10H11-3) (η (Pa.s))
HPMC K4M (3.97) / HPC GF (1.98) / PEG 400 (3.97) (10H09-4) (η (Pa.s))
HPMC K4M (7.95) / PEG 400 (1.98) (10G13-6) (η (Pa.s))
HEC 250 HX (7.95) / PEG 400 (1.98) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
HEC 250 HX (7.95) / PEG 400 (1.98) (η (Pa.s))
HEC 250 M (9.54) / PEG 400 (1.98) (η (Pa.s))
HPMC K4M (6.36) / PEG 400 (1.98) (10H05-8) (η (Pa.s))
HPMC E5 (31.83) / PEG 400 (7.95) (10G13-9) (η (Pa.s))
HPMC E5 (15.91) / PEG 400 (3.97) (10E05-4) (η (Pa.s))
HPMC E15 (7.95) / PEG 400 (1.98) (10G05-8) (η (Pa.s))
HPMC E5 (7.95) / PEG 400 (1.98) (10E04-2) (η (Pa.s))

Figure16 Cont.





Figure 17


Eponges à base de cidofovir
Cidofovir dihydraté
20 mW
°C
min
METTLER TOLEDO STARe System
Technologie Pharmaceutique ULg: METTLER